Literature DB >> 2454643

Human class I MHC-restricted cytotoxic T-lymphocytes specific for human immunodeficiency virus envelope antigens.

D H Shepp1, F Daguillard, D Mann, G V Quinnan.   

Abstract

Vaccines incorporating HIV envelope antigens are being developed for the prevention of AIDS. To determine whether HIV envelope antigens are recognized by human cytotoxic T-lymphocytes (CTL), we assessed class I MHC-restricted, HIV envelope antigen-specific cytotoxic activity of peripheral blood mononuclear cells (PBMC) from HIV-infected individuals, following in vitro stimulation. The target cells were human skin fibroblasts of known tissue type, infected with recombinant vaccinia viruses, either containing or lacking the whole HIV envelope gene. Ten out of 17 (59%) asymptomatic HIV-seropositive individuals demonstrated HIV envelope antigen-specific cytotoxicity at levels that were above those seen in HIV-seronegative controls. MHC restriction of cytotoxicity was evident in that 13 out of 19 (68%) of the targets matched for the tissue type of the donor at one or more class I MHC loci were lysed, but only two out of 18 (11%) mismatched targets (P = 0.0004). Both partial purification of effector cells and evidence of MHC restriction indicated that T-lymphocytes were responsible for the observed cytotoxicity. HIV envelope antigen-specific CTL can be detected following in vitro stimulation of the PBMC in many asymptomatic HIV-seropositive individuals. HIV envelope antigens are recognized by human CTL and are, therefore, potentially relevant immunogens for induction of HIV-specific CTL responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454643     DOI: 10.1097/00002030-198804000-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections.

Authors:  G Vanham; L Kestens; P Gigase; R Colebunders; M Vandenbruaene; L Brijs; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

2.  An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes.

Authors:  A Hosmalin; M Clerici; R Houghten; C D Pendleton; C Flexner; D R Lucey; B Moss; R N Germain; G M Shearer; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins.

Authors:  Y Riviere; F Tanneau-Salvadori; A Regnault; O Lopez; P Sansonetti; B Guy; M P Kieny; J J Fournel; L Montagnier
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.

Authors:  R A Koup; C A Pikora; K Luzuriaga; D B Brettler; E S Day; G P Mazzara; J L Sullivan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.